Navigation Links
ImpactRx Announces Expansion and Addition of Physician Information Networks
Date:11/2/2007

Data Expanded for Oncology, Neurology and Urology; Initiated for

Dermatology and OB/GYN

MOUNT LAUREL, N.J., Nov. 2 /PRNewswire/ -- ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on physicians' prescribing behavior, announced today that it is expanding its nationwide physician information networks in alignment with emerging market trends and rising client demand. ImpactRx is increasing the size of its longitudinal, smartphone-enabled physician research panels in three key specialties, and is initiating data collection in two additional specialties to broaden the scope of its data and services.

ImpactRx recently increased the size of its neurology specialty panel by 50 percent, is completing a similar-sized increase to its panel of urologists, and plans to expand its groundbreaking oncology research panel beginning in the first quarter of 2008.

"The oncology market has become increasingly competitive as the availability of new treatment alternatives grows and companies promote more aggressively for a share of the oncologist's attention," said Jill Walton, recently appointed Managing Director and Vice President of ImpactRx's Oncology Business Unit. "Clients need to accurately assess performance, and ImpactRx's point-of-promotion and point-of-treatment model provides unmatched insight into sales execution and effectiveness. This expansion enhances our ability to provide our clients with the information edge needed to compete and win in the oncology marketplace," said Walton.

In addition to expanding its existing physician panels, ImpactRx is adding new panels for two important specialties, dermatologists and obstetricians/gynecologists.

"This extension of our information networks puts us in a stronger position to support trends emerging across our customer base," said John Kain, ImpactRx's Vice President of Marketing. "We will be much better situated to support the growing areas of neuroscience, vaccines and oncology. With the addition of a psoriasis-focused dermatology panel to our existing rheumatology and gastroenterology panels, we can offer our biologic clients a comprehensive research solution in the fast-growing inflammation category." Kain continued, "We are uniquely able to capture usage of infused as well as injected products, and to separate treatment and promotion activity according to indication for the many brands that are used and promoted for multiple conditions. Concurrent with this expansion effort, we will continue working diligently to improve the value we provide through our existing core primary care and specialty panels."

With the addition of dermatologists and obstetricians/gynecologists to such specialties as cardiology, endocrinology and psychiatry, ImpactRx now has eleven distinct physician specialties represented within its nationwide information networks. ImpactRx's proprietary data-capture and analysis methodology directly links promotional activity to treatment decisions across all its physician networks, including the expanded and new panels.

"Our expansion initiative is a direct response to our customers' growing need for insight into the effectiveness of their sales and marketing efforts to an increasing number of physician specialty groups," said Richard Altus, ImpactRx's CEO. "This is an area for which data has been limited, so we are committed to extending our unique capabilities to respond to our clients' emerging information and analytical needs."

About ImpactRx

Founded in October 2000, ImpactRx's physician networks are the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and for measuring their impact on physician prescribing behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (http://www.mediphaseventure.com), Oxford Bioscience Partners (http://www.oxbio.com), Merck Capital Ventures (http://www.merckcapitalventures.com) and 3i Group (http://www.3i.com).

CONTACT:

Patrick Angelastro

Sr. Vice President, Strategic Development

ImpactRx, Inc.

856-273-0221, ext. 102

pangelastro@impactrx.com


'/>"/>
SOURCE ImpactRx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to the ... brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Kim to the CDG team” said President and Managing Partner Dr. Steven A. Kolenik ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... ... ... From a health perspective, 2017 will clearly be the Year of the Gut. ... health and general physical well-being. The New York Times suggested a “ Gut Makeover ... Charlottesville restaurant, good gut health is clearly on the menu. Threepenny Cafe ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for ... V, its official endurance training and fundraising team, to compete in the Boston Marathon ... those inspired to finish the world’s oldest annual marathon to join Team V and ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: